The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...

Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...

Gireesh Babu, New Delhi Wednesday, March 5, 2025, 14:45 Hrs [IST] With the registration of clinical research organisations (CROs) to b ...

Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from ...

A new drug that works against the main types of primary bone cancer has been developed by researchers at the University of ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its ...

A research team funded by the National Institutes of Health (NIH) has developed a medication that shows promise in treating acute and chronic pain.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...